Resource for Minority Patient Recruitment

项目总结 CDU/UCI癌症中心伙伴关系的临床试验单位资源(CTUR)部分将负责促进少数人参与临床研究和临床试验的总体目标。这一目标的实现将通过利用现有的临床研究设施和资源，进一步发展CDU在癌症相关临床试验领域的机构能力。具体地说，合作伙伴关系将 加强CDU现有的临床研究中心(CRC)；CRC的临床试验部分，称为临床研究卓越中心(CCRE)，是为了加强CDU的临床研究基础设施而开发的，由Mayer Davidson博士领导。CDU和加州大学洛杉矶分校的合作伙伴关系将继续建立在现有基础设施的基础上，以增强在癌症健康差异方面进行有效临床研究的能力。资源活动的具体目标如下： 具体目标1：在儿童权利中心加强招募和保留少数族裔参加与癌症有关的临床试验； 具体目标2：在CDU临床癌症研究研究的设计、开发和执行方面提供培训和援助； 具体目标3：通过外联方案与社区交流和征求对临床试验的反馈；以及 具体目标4：聘请外部评审员评估临床结果的质量和强度。这些审查员将在最早的时候参与，为临床研究的发展提供意见。

PROJECT SUMMARY The Clinical Trials Unit Resource (CTUR) component ofthe CDU/UCI^ Cancer Center Partnership will be charged with the overarching goal of enhancing minority participation in clinical research and clinical trials. The accomplishment of this goal will further develop the institutional capacity at CDU in the area of cancer-related clinical trials by leveraging existing clinical research facilities and resources. Specifically, the partnership will enhance the established Clinical Research Center (CRC) at CDU; the clinical trials component ofthe CRC, called the Clinical Center for Research Excellence (CCRE), was developed to enhance CDU's infrastructure for clinical studies and is headed by Dr. Mayer Davidson. The CDU-UCLA partnership will continue to build upon the current infrastructure to enhance the ability to conduct effective clinical studies in cancer heath disparities. The specific objectives of the Resources activities are as follows: Specific Aim 1: Enhance the recruitment and retention of racial and ethnic minorities into clinical trials related to cancer at the CRC; Specific Aim 2: Provide training and assistance in the design, development, and execution of CDU clinical cancer research studies; Specific Aim 3: Communicate and solicit feedback regarding clinical trials with the community via the Outreach Program; and Specific Aim 4: Employ external reviewers to assess the quality and strength ofthe clinical results. These reviewers will be engaged at the eariiest onset to provide input in the development of clinical studies.